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Abstract
Background: To review our experience and evaluate treatment planning using intensity-modulated radiotherapy
(IMRT) and helical tomotherapy (HT) for the treatment of elderly patients with bladder cancer.
Methods: From November 2006 through November 2009, we enrolled 19 elderly patients with histologically
confirmed bladder cancer, 9 in the IMRT and 10 in the HT group. The patients received 64.8 Gy to the bladder
with or without concurrent chemotherapy. Conventional 4-field “box” pelvic radiation therapy (2DRT) plans were
generated for comparison.
Results: The median patient age was 80 years old (range, 65-90 years old). The median survival was 21 months (5
to 26 months). The actuarial 2-year overall survival (OS) for the IMRT vs. the HT group was 26.3% vs .37.5%,
respectively; the corresponding values for disease-free survival were 58.3% vs. 83.3%, respectively; for locoregional
progression-free survival (LRPFS), the values were 87.5% vs. 83.3%, respectively; and for metastases-free survival, the
values were 66.7% vs. 60.0%, respectively. The 2-year OS rates for T1, 2 vs. T3, 4 were 66.7% vs. 35.4%, respectively
(p = 0.046). The 2-year OS rate was poor for those whose RT completion time greater than 8 weeks when
compared with the RT completed within 8 wks (37.9% vs. 0%, p = 0.004).
Conclusion: IMRT and HT provide good LRPFS with tolerable toxicity for elderly patients with invasive bladder
cancer. IMRT and HT dosimetry and organ sparing capability were superior to that of 2DRT, and HT provides better
sparing ability than IMRT. The T category and the RT completion time influence OS rate.
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Background
Radical cystectomy with pelvic lymph node dissection
has long been the standard of care for invasive bladder
cancer. However, the procedure involves removal of the
bladder, surrounding structures (including the prostate
gland or uterus), regional lymph nodes, with urinary
diversion. Accordingly, radical cystectomy often results
in considerable morbidity, including incontinence and
impotence [1,2]. Due to the potential morbidity and for
patients whose conditions are not amenable to curative
treatment and for whom palliative treatment (organ pre-
servation) is the best choice, multiple modalities have
been the topic of recent investigations. There are several
groups that have reported the value of combined-modal-
ity therapy, including transurethral resection (TURBT)
of the bladder tumor, radiation therapy (RT), and sys-
temic chemotherapy [3-7]. The elderly patients, how-
ever, may have age-related changes in their physiology,
which alter their tolerance to full course radiotherapy
and are generally medically unfit for cystectomy [8].
The morbidity in the bladder cancer treated with RT
is well known [9]. Of the patients treated with RT,
45.7% had severe reactions in the bladder and 8.5% had
severe reactions in the bowel. Of the Radiation Therapy
Oncology Group (RTOG) patients, 7% experienced late
grade 3+ pelvic toxicity [10]. In the initial results of
RTOG 95-06, 21% of patients with muscle-invading
bladder cancer developed grade 3 or 4 hematologic toxi-
city with TURBT plus concurrent chemoradiation ther-
apy (CCRT) [11]. The RT technique used in these
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be reduced to critical organs, and thus, causes unavoid-
able side effects.
For tumors located in the pelvis improvements in
treatment planning and delivery have evolved from con-
ventional to intensity-modulated radiotherapy (IMRT)
[12]. For example, under similar target coverage, IMRT
is superior to conventional techniques in normal tissue
sparing for the treatment of cervical cancer, and a num-
ber of groups have explored IMRT in the gynecologic
setting as a method to minimize the gastrointestinal,
genitourinary, and bone marrow toxicity that occurs
with conventional RT [13-15].
Helical tomotherapy (HT), an image-guided IMRT,
delivers highly conformal dose distributions to the tar-
gets, with simultaneous critical organ sparing [15,16].
Owing to the shape and location, the extent of bladder
tumors make them well suited for HT. In our institute,
a Tomotherapy Hi-Art System (Tomotherapy, Inc.,
Madison, Wisconsin, USA) was placed into service in
November 2006. We report our initial clinical experi-
ence with bladder cancer patients treated with IMRT or
HT for organ preservation, focusing on feasibility of
IMRT and HT, clinical outcome, and early toxicities.
Methods
Patient characteristics
Between November 2006 and November 2009, we retro-
spectively reviewed the medical records of 25 patients
with muscle-invasive (T2 to T4) or high-risk T1-bladder
cancer were treated with either RT (n = 12) alone or
with CCRT (n = 13) after initial TURBT of the tumor.
Risk factors for T1-cancer were defined as tumor grade
3/4, associated carcinoma-in situ, multifocal tumors, or
recurrent tumors refractory to repeated TURBT with or
without intravesical therapy. Excluded from analysis
were six patients in whom treatment was regarded to be
palliative because of concomitant distant disease or in
which the radiation dose to the bladder was insufficient
(less than 45 Gy), or they were younger than 65 years.
All of the remaining 19 patients (9 who had IMRT and
10 who had HT) were free of distant metastases at the
time of RT/CCRT. Pelvic lymph node metastases
(detected by computed tomography or ultrasound), mul-
tiple TURBTs before RT/CCRT, or poor general condi-
tion with contraindications for radical cystectomy were
not considered exclusion criteria. Patient and tumor
characteristics are listed in Table 1. The disease was
staged according to the American Joint Committee on
Cancer staging classifications 6
th edition.
Radiotherapy
RT/CCRT was initiated 4 to 8 weeks after initial TURBTs
using 6-MV photons and a 7-filed IMRT or HT technique
with daily fractions of 1.8 Gy in five consecutive days. A
total of 10 patients were treated by RT alone (six with
IMRT and four with HT). Chemotherapy was given during
RT and consisted of weekly cisplatin (30 mg/m
2) in three
patients or carboplatin (area under the curve [AUC] of 4-6
mg/mL. min) every 21 days in two patients with decreased
creatinine clearance (< 60 mL/min) or congestive heart dis-
ease. A combination of weekly cisplatin (30 mg/m
2)a n d
weekly 5-fluorouracil (5-FU) (450 mg/m
2)w a sg i v e nt oo n e
patient. A combination of gemcitabine (800-1000 mg/m
2)
and carboplatin (AUC of 4-6 mg/mL. min) on days 1 and 8
of a 3-week cycle was given to three patients (Table 1).
Immobilization
The BlueBAG™ immobilization system (Medical Intelli-
gence, Schwabmünchen, Germany) was used to
Table 1 Patient characteristics
IMRT HT All
No. of patient (%)
Age (years)
Mean 79.9 78.5 79.2
Range 66-90 65-89 65-90
Gender
Male 7 (77.8%) 7 (70%) 14
(73.7%)
Female 2 (22.2%) 3 (30%) 5 (26.3%)
Karnofsky performance status
< 6 0 000
≥ 60 9 (100%) 10 (100%) 19 (100%)
Pathology
Urothelial carcinoma 9 (100%) 10 (100%) 19 (100%)
Tumor stage
Stage I 0 1 (10%) 1 (5.3%)
Stage II 2 (22.2%) 2 (20%) 4 (21.1%)
Stage III 4 (44.4%) 4 (40%) 8 (42.1%)
Stage IV 3 (33.3%) 3 (30%) 6 (31.6%)
Primary Tumor stage
T1-high risk 0 1 (10%) 1 (5.3%)
T2 2 (22.2%) 3 (30%) 5 (26.3%)
T3 5 (55.6%) 3 (30%) 8 (42.1%)
T4 2 (22.2%) 3 (30%) 5 (26.3%)
Regional Lymph Node stage
N0 6 (66.7%) 7 (70%) 13
(68.4%)
N1 2 (22.2%) 1 (10%) 3 (15.8%)
N2 1 (11.1%) 2 (20%) 3 (15.8%)
Concurrent with chemotherapy 3 (33.3%) 6 (60%) 9 (47.4%)
Median dose for RT completion
(range) (Gy)
57.6 (45-
64.8)
57.6 (54-
64.8)
57.6 (45-
64.8)
Median time for RT completion
(range) (wks)
7 (6-11) 6.5 (5-10) 7 (5-11)
Abbreviations:
All = all Patients in the study; HT = helical tomotherapy; IMRT = intensity-
modulated radiation therapy; RT = radiation therapy
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supine with arms folded across the chest with ankle sup-
ports. The bladder was emptied immediately before scan-
ning and treatment. All patients underwent a 5-mm slice
thickness CT planning scan (Siemens Somatom Plus 4 CT
scanner) from the L1 to 5 cm below the ischial tuberos-
ities. Target objects and normal structures were contoured
with a Pinnacle 3 treatment planning system (Philips
Healthcare, Madison, Wisconsin, USA). The MRI or CT
images were retrieved on a Pinnacle workstation and fused
with the CT images for contouring of the tumor volume.
Delineation of target volumes
The gross tumor volume (GTV) was defined as all
known gross disease determined by CT, clinical infor-
mation, and MRI. The clinical target volume (CTV) was
defined as the GTV, the whole bladder, and pelvic
lymph nodes [17-19]. In patients with tumors at the
bladder base, the proximal urethra, and in men, the
prostate and prostatic urethra, were included in the
CTV. The nodal CTV included the internal (hypogastric
and obturator) and external iliac lymph nodes and peri-
nodal tissue [20]. Seven mm was extended from the ves-
sels as the margin of nodal CTV. Bone and
intraperitoneal small bowel was excluded from the
nodal CTV; in addition, the iliopsoas muscle that lies
adjacent to clinically negative lymph nodes was also
excluded from the nodal CTV. The most antero-lateral
external iliac lymph nodes positioned just proximal to
the inguinal canal were excluded from the nodal CTV.
T h eC T Vo ft h en o d e se n d e d7m mf r o mt h eL 5 / S 1
interspace to account for the PTV. The PTV for nodes
stopped at the L5/S1 interspace. The planning target
volume (PTV) provided a 7-mm margin (anteriorly, pos-
teriorly, laterally, as well as superiorly and inferiorly)
around the nodal CTV as PTV nodal [15] and a 1 to 1.5-
cm margin for CTV as PTV [21-23]. The sequential
boost field of CTV was defined as the GTV (primary
tumor and any extravesical spread). The boost field of
the PTV consisted of a 1.5-cm margin around the CTV
boost edges except superiorly where the extension was
2.5 cm. These margins incorporated internal margins
and set-up margins [24,25]. The treatment plan used for
each patient was based on an analysis of the volumetric
dose, including dose volume histogram (DVH) analyses
of the PTV and critical normal structures.
The 90% isodose surface covered between 95% and 98%
of the PTV, or volumes of overdose exceeding 115% < 5%
of the PTV volume were considered acceptable. The field
width, pitch, and modulation factor usually used for the
HT treatment planning optimization were 2.5 cm, 0.32,
and 3.0, respectively. All HT-treated patients received
daily megavoltage computed tomography (MVCT) acqui-
sitions for setup verification [26]. The organs at risk
(OARs) were contoured using the empty-bladder CT
scan. Dose-volume constraints for normal tissues were as
follows: small bowel (2 cm above the most superior vessel
contour) 250 cc received < 45 Gy; femoral head V30 <
15%; rectum V30 < 50%, V55 < 10%. The rectum volume
was defined on CT from the anus (at the level of the
ischial tuberosities) for a length of 15 cm, or to the recto-
sigmoid flexure.
Conventional treatment planning for comparison
Conventional whole pelvic radiation therapy (2DRT)
plans were generated using the Pinnacle 3 Treatment
Planning System (Philips Healthcare, Madison, Wiscon-
sin, USA). A 4-field “box” plan was designed using 6-
MV photons with apertures shaped to the PTV in each
beam’s eye-view. The field margins in the inferior and
superior dimensions extended 1 cm below the lower
pole of the obturator foramen to the mid-sacrum (the
anterior aspect of the S1-S2 junction). Laterally, the
anterior and posterior opposed fields extended at least
1.5 cm beyond the widest point of the bony margin of
the pelvis. For the parallel opposed lateral fields, the
field edges extended 3.0 cm posterior to the CTV blad-
der and extended 1 cm anterior to the most anterior
point of the symphysis pubis or 1.5 cm anterior to the
anterior tip of the bladder, whichever was the most
anterior. Superiorly, the lateral fields included blocks
anteriorly to exclude the small bowel and the anterior
rectus fascia. At least 98% of the PTV were encom-
passed by the prescribe doses.
Dose-volume analysis of treatment plans
The conformity index (CI) was originally proposed by
Paddick [27] to evaluate the tightness of fit of the plan-
ning target volume to the prescription isodose volume
in treatment plans as follows,
CI = (VPTV/TVPV)/(TVPV/VTV) (1)
where VPTV is the volume of the PTV, VTV is the trea-
ted volume enclosed by the prescription isodose surface,
and TVPV is the portion of the PTV within the pre-
scribed isodose volume. The uniformity index (UI) was
defined as D5%/D95%,w h e r eD 5% and D95% were the
minimum doses delivered to 5% and 95% of the PTV, as
previously reported [28].
Toxicity
Interruptions in radiotherapy could be necessitated by
uncontrolled diarrhea, or other acute complications. If
radiation therapy was temporarily stopped, then che-
motherapy was also stopped. Chemotherapy was nor-
mally stopped at the completion of RT. If
chemotherapy was stopped, RT would continue. RT
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non-hematologic toxicity until toxicity resolved at least
to grade 3 or less. Chemotherapy was withheld in any
case involving grade 3 toxicity until the toxicity
regressed to any grade of < 3; in patients with grade 3
toxicity that persisted longer than 2 weeks, chemother-
apy was no longer administered.
Follow-up
Upon treatment completion, patients were evaluated
every 3 months for the first year, every 4 months during
the second year, every 6 months during the third year,
and annually thereafter. At each visit, a physical and
pelvic examination, blood counts, clinical chemistry,
chest x-rays and cystoscopies were performed. CT,
ultrasonography, and other imaging studies were con-
ducted when appropriate. Suspected cases of persistent
or recurrent disease were confirmed by biopsy whenever
possible. Acute and late toxicities (occurring > 90 days
after beginning RT) were defined and graded according
to the Common Terminology Criteria for Adverse
Events v3.0.
Statistical methods
Descriptive statistics (means, medians, and proportions)
were calculated to characterize the patient, disease, and
treatment features as well as toxicities after treatment.
The overall survival (OS), progression-free survival
(PFS), locoregional progression-free survival (LRPFS),
and metastases-free survival (MFS) rates were estimated
using the Kaplan-Meier product-limit method. Progres-
sion was defined as a 50% increase in the product of the
two largest diameters of the primary tumor or metasta-
sis. Progression-free survival was calculated from the
date of pathologic proof to the date of the first physical
or radiographic evidence of disease progression, death,
or the last follow-up visit. Survival was calculated from
the date of pathologic proof to the date of death or the
last follow-up visit. All analyses were performed using
SPSS, version 12.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Table 1 details the patient characteristics. Fourteen men
and five women were included (nine in the IMRT group
and 10 in the HT group). They had a median age of 80
years (range, 65-90 years). All patients had urothelial car-
cinoma. Only 5% of the patients had a T1 high-risk pri-
mary tumor, while 95% had T2-4 tumors; 32% were node
positive. The disease stage distribution was as follows: 1
Stage I (5%), 4 Stage II (21%), 8 Stage III (42%), and 6
S t a g eI V( 3 2 % ) .T h em e d i a nd o s eo fR Tf o ra l l ,I M R T -
and HT-treated group was 57.6 Gy. The median duration
of RT for all, IMRT- and HT-treated groups was 7, 7 and
6.5 weeks, respectively. The characteristics of patients in
the IMRT and HT groups were similar (Table 1).
Treatment outcome
The median survival was 21 months (range, 5-26
months). Of the 19 eligible patients, 17 (89.5%) had no
local recurrence. Only two patients experienced recur-
rence, one in the IMRT and one in the HT group. The
actuarial 2-year OS, DFS, LRPFS, and MFS for all vs. the
IMRT group vs.t h eH Tg r o u pw e r e3 3 . 2 %vs.2 6 . 3 %vs.
37.5%, 63.6% vs.5 8 . 3 %vs. 83.3%, 84.9% vs.8 7 . 5 %vs.
83.3% and 59.0% vs. 66.7% vs. 60.0%, respectively (Figure
1, Figure 2, Figure 3, Figure 4). There are not statisti-
cally differences between both groups about OS, DFS,
LRPFS, and MFS. T stage affected the OS rate of the
elderly, which for T1/2 vs. T3/4 was 66.7% vs. 35.4% (p
= 0.046). The 2-year OS rate for stage I/II vs. stage III/
IV was 66.7% vs. 39.1% (p = 0.07) There were 4 patients
with RT completion times greater than 8 wks (In IMRT
group: one is 10 wks and the other is 11 wks; In HT
group: one is 9 wks and the other is 10 wks) and The
patients with RT completion times greater than 8 weeks
had poorer 2-year OS rates (37.9% vs. 0%, p = 0.004).
Dose-volume analysis
Comparing 2DRT with IMRT and HT, the UI and CI
were 1.10 ± 0.03 vs. 1.09 ± 0.01 vs. 1.01 ± 0.01 and 3.17
± 1.01 vs. 1.22 ± 0.06 vs. 1.20 ± 0.03, respectively. The
mean of V30 for the right and left side femoral heads
for the three RT modalities were 74% vs. 35% vs. 6%
Figure 1 The actuarial overall survival rates at 2 years for all
bladder cancer patients and the patients treated with
intensity-modulated radiation therapy (IMRT) and helical
tomotherapy (HT).
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tion dosages (Gy) to the rectum and intestines for the
three RT modalities were 50 Gy vs. 34 Gy vs. 25 Gy and
40 Gy vs. 29 Gy vs. 21 Gy, respectively. The compari-
sons of dose-volume histogram statistics for the organs
at risk (OARs) are described in Table 2 and Figure 5.
Acute toxicity
No grade 3 of acute toxicity for thrombocytopenia, diar-
rhea, and nausea/vomiting occurred in either group.
Only one IMRT-treated patient suffered from grade 2 of
diarrhea during treatment. The other IMRT-treated and
HT-treated patients experienced grade 1 diarrhea and
nausea/vomiting. In the IMRT-treated group, two
patients experienced grade 3/4 anemia and two experi-
enced grade 3 leukopenia. In the HT-treated group, only
one patient experienced grade 3 anemia and no patient
experienced grade 3 leukopenia.
Discussion
This preliminary study showed that IMRT and HT both
produce minimal grade 3 or greater toxicity and provide
good LRPFS. This supports the use of these modalities
in elderly patients. HT provided better UI and OAR
sparing than IMRT. The T category and the RT comple-
tion time (longer than 8 weeks) were statistically signifi-
cantly associated with OS.
The RTOG 97-06 study showed that RT given concur-
rently with or without chemotherapy provided benefits
for locally advanced bladder cancer patients [29]. For
elderly patients with locally advanced bladder cancer,
several reports concluded that RT also was an effective
treatment option for elderly patients who were not sui-
table for cystectomy. Santacaterina et al. [30] reported
that elderly patients with muscle-invasive bladder cancer
who underwent RT had a median survival of 21.5
months. Additionally, Sengelov and coworkers [31]
Figure 2 The actuarial disease-free survival rates at 2 years for
all bladder cancer patients and the patients treated with
intensity-modulated radiation therapy (IMRT) and helical
tomotherapy (HT).
Figure 3 The actuarial locoregional progress-free survival rates
at 2 years for all bladder cancer patients and the patients
treated with intensity-modulated radiation therapy (IMRT) and
helical tomotherapy (HT).
Figure 4 The actuarial metastasis-free survival rates at 2 years
for all bladder cancer patients and the patients treated with
intensity-modulated radiation therapy (IMRT) and helical
tomotherapy (HT).
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in elderly patients, with 29% surviving for 2 years. The
overall actuarial median survival under 2DRT techni-
ques in these reports ranged from 9 to 21.5 months
[30,32,33]. In our institute, the median survival is 21
months. The actuarial 2-year OS, DFS, LRPFS, and MFS
rates in the study were 33%, 64%, 85%, and 59%, respec-
tively. (Figure 1, Figure 2, Figure 3, Figure 4) These
dates are compatible with the previous reports suggest-
ing IMRT and HT are feasible for elderly patients with
locally advanced bladder cancer.
RT concurrent with chemotherapy, or alone, provides
benefits for locally advanced bladder cancer patients.
However, patients developed grade 3 or 4 hematologic
toxicity or pelvic toxicities in the studies where radiation
was delivered by conventional RT techniques. In the
RTOG 95-06 study, 21% of patients with muscle-invad-
ing bladder cancer who underwent TURBT plus CCRT
had grade 3 or 4 hematologic toxicity and 15% had
grade 3 bowel toxicity [11]. Among the bladder cancer
patients treated with RT or CCRT after TURBT, 25%
had grade 3/4 hematologic toxicities and 10% had grade
3/4 bowl toxicities [18]. Similar results were also
reported by Hagan et al [29]. In induction and consoli-
dation regimens, the percentages of grade 3/4 hematolo-
gic toxicities were 11%/2% and 11%/0%, respectively.
The grade 3/4 bowel toxicity rate in induction and con-
solidation regimens was 9%/0% and 0%/4%, respectively.
In the current study, none of elderly patients suffered
from grade 3 or 4 acute bowel toxicities. IMRT and HT
had statistically significantly better organ sparing results
than 2DRT (Table 2). van Rooijen DC et al. [34] also
mentioned the similar report with IMRT for bladder
cancer that a statistically significant dose decrease to the
small intestines can be achieved while covering both
tumour and elective PTV adequately. In addition, HT
had better OAR sparing ability than IMRT did in the
current study. (Figure 5) Three of 19 patients (16%)
experienced grade 3/4 anemia, two in the IMRT group
and one in the HT group. Two of 19 patients (11%)
experienced grade 3 leukopenia in the IMRT group. We
believe that IMRT or HT has potential benefits for
reducing the toxicities caused by 2DRT.
Dose homogeneity is a part of objective function and
IMRT plan optimization is aimed at improving the value
of the objective function. Dose CI is not included as a
part of the objective function. The CI is usually larger
than 1, indicating that a portion of the prescription dose
was delivered outside the PTV. The greater CI is the
less dose conformity to the PTV and a greater UI indi-
cates higher heterogeneity in the PTV [27,28]. Compar-
i n g2 D R T ,I M R T ,a n dH Tf o rU Ia n dC I ,b o t hI M R T
Table 2 Comparison of dosimetric parameters for irradiation of bladder cancer and normal organs at risk (OARs) by
using different treatment techniques.
IMRT HT 2DRT P value
PTV UI 1.09 ± 0.01 1.01 ± 0.01 1.10 ± 0.03 IMRT vs. HT: p = 0.001
2DRT vs. IMRT: p = 0.19
2DRT vs. HT: p = 0.002
CI 1.22 ± 0.06 1.20 ± 0.03 3.17 ± 1.01 IMRT vs. HT: p = 0.19
2DRT vs. IMRT: p < 0.001
2DRT vs. HT: p < 0.001
Right Femoral head (V30) mean
(%)
35.0 ± 0.2 6.0 ± 0.1 73.7 ± 19.7 IMRT vs. HT: p = 0.001
2DRT vs. IMRT: p < 0.001
2DRT vs. HT: p < 0.001
Left Femoral head (V30) mean
(%)
26.5 ± 0.3 6.1 ± 0.1 71.1 ± 22.9 IMRT vs. HT: p = 0.03
2DRT vs. IMRT: p < 0.001
2DRT vs. HT: p < 0.001
Rectum mean (Gy) 34.3 ± 9.1 25.4 ± 5.9 50.4 ± 8.1 IMRT vs. HT: p = 0.019
2DRT vs. IMRT: p < 0.001
2DRT vs. HT: p < 0.001
V55Gy < 50%
(%)
4.7 ± 9.6 1.4 ± 2.8 46.1 ± 36.8 IMRT vs. HT: p = 0.28
2DRT vs. IMRT: p = 0.001
2DRT vs. HT: p < 0.001
Intestine mean (Gy) 29.2 ± 9.3 20.7 ± 6.6 40.2 ± 13.2 IMRT vs. HT: p = 0.034
2DRT vs. IMRT: p = 0.034
2DRT vs. HT: p < 0.001
250 c.c.
<4 5G y
(c.c.)
25.9 ± 30.1 10.8 ± 11.9 192.6 ± 132.6 IMRT vs. HT: p = 0.16
2DRT vs. IMRT: p = 0.001
2DRT vs. HT: p < 0.001
The Vx is the percentage of femoral head volume that receives ≥ X Gy in the total femoral head volume.
Abbreviations:
2DRT: Conventional whole pelvic radiation therapy; CI: Conformal index; IMRT = intensity-modulated radiation therapy; HT = helical tomotherapy; UI: Uniformity
index.
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0.001). HT provided the better homogeneity than IMRT
(p = 0.001) and 2DRT (p = 0.002). Among the patients,
the additional freedom in inverse planning optimization
of 51 beam angles for HT usually results in a more uni-
form target dose, and better avoidance of OARs com-
pared to IMRT (Table 2).
Several studies show that the most important factor
affecting treatment outcome in bladder cancer is T-
stage [18,35-37]. Rodel et al. [18] noted that overall sur-
vival at 5 and 10 years was 75% and 51% for T1 tumors
and 45% and 29% for muscle invasive disease, respec-
tively. Cowan et al. [35] found that the 5-year OS rates
for patients with bladder cancer were 70% for T2 disease
and 51% for T3 disease. Shipley [36] also noted that the
5-year actuarial overall survival rates for T2 and T3-T4a
were 62% and 41%, respectively. The 5-year overall sur-
vival rates for T1-T3a and T3b-T4b disease reported by
Fokdal et al. [37] were 31% and 3%, respectively. In the
current study, the 2-year OS rates for T1/2 vs. T3/4 dis-
ease were 66.7% vs. 35.4% (p =0 . 0 4 6 ) .W ea l s oc o n -
firmed that survival rates of elderly bladder cancer
patients are related to T-stage.
RT treatment duration is a prognostic factor for OS of
head and neck cancer. Langendijk et al. [38] reported
that the OS rate with RT treatment durations ≤ 8 weeks
and > 8 weeks were 52% and 16%, respectively. We also
saw a similar phenomenon in our study of elderly blad-
der cancer patients. When the RT completion time is >
8 weeks patients have poorer 2-year OS rates than when
RT treatment time is ≤ 8 weeks (0% vs. 37.9%, p =
0.004).
Conclusions
Among our 19 patients, IMRT and HT dosimetry and
organ sparing capability were superior to that of
Figure 5 The comparisons of dose-volume histogram of planning target volume (PTV) and organs at risk for one of intensity-
modulated radiation therapy (IMRT) - treated patients, one of helical tomotherapy (HT) - treated patients and one of the patients
replanned by conventional box techniques (2DRT). (A) PTV. (B) Rectum. (C) Intestine. (D) Femur head.
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mal grade 3 or greater toxicity and provide good
LRPFS. The T category and the RT completion time
would affect the OS of bladder cancer. Long-term fol-
low-up is needed to confirm these preliminary
findings.
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